Volatile Week, but Green? Click to watch the new Podcast.

Alimera Sciences Stock Forecast

NASDAQ:ALIM BUY SELL

$5.22 (-4.40%)

Volume: 10.172k

Closed: Jul 05, 2022

Hollow Logo Score: -5.265

Alimera Sciences Stock Forecast

BUY SELL NASDAQ:ALIM
$5.22 (-4.40%)

Volume: 10.172k

Closed: Jul 05, 2022

Score Hollow Logo -5.265

Alimera Sciences Company Profile

6120 Windward Parkway

Alpharetta GA 30005

678-990-5740

www.alimerasciences.com

Industry: Drug Manufacturers

Sector: Healthcare

Alimera Sciences

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a constant micro-dose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. It has license agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE